QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=7116CFF2C305E39B6A5ADB16A592939D;jsessionid=0B3561E72662FBE6EB77424C6CF9E852;jsessionid=48FD400854722EAA9233B97BBB9A4283;jsessionid=60238739B2F34634A15F586986642293;jsessionid=6144F063B2F5DD43A1EEF5065A9004B5;jsessionid=EA9EF403ADE72CB4BFA9C36863A5226D (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=7116CFF2C305E39B6A5ADB16A592939D;jsessionid=0B3561E72662FBE6EB77424C6CF9E852;jsessionid=48FD400854722EAA9233B97BBB9A4283;jsessionid=60238739B2F34634A15F586986642293;jsessionid=6144F063B2F5DD43A1EEF5065A9004B5;jsessionid=EA9EF403ADE72CB4BFA9C36863A5226D